Paterson, New Jersey Clinical Trials

A listing of Paterson, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 …

selinexor
neutrophil count
MRI
methylated
corticosteroids
Hackensack Meridian Health, 92 Second Street
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

paclitaxel
olaparib
carcinosarcoma
maintenance therapy
sarcoma
Research Site
 (6.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

stage iia lung squamous cell carcinoma ajcc v7
cisplatin
pembrolizumab
monoclonal protein
HIV Infection
Neurosurgeons of New Jersey-Ridgewood
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
bethesda assay
factor ix
hemophilia
haemophilia a
Investigational Site Number 8400008
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

parenteral administration
hepatitis b surface antigen
antibiotic therapy
isatuximab
corticosteroids
Investigational Site Number 8400006
 (6.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
bethesda assay
factor ix
hemophilia
haemophilia a
Investigational Site Number 8400008
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

BRAF
stage iv non-small cell lung cancer
adjuvant therapy
vitamin b12 level
pemetrexed
New Jersey Cancer Care and Blood Disorders (NJCCBD)
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

epidermal growth factor
stage iv non-small cell lung cancer
small cell lung cancer
lung cancer
pembrolizumab
Hackensack Univ Med Ctr /ID# 216484
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

acupuncture
pain management
high dose chemotherapy
opioid
high-dose chemotherapy
Hackensack Meridian Health
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Double-Blind Multicenter Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

This clinical trial will examine if a new treatment of Mesenchymal Stems Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.

SARS
covid-19
acute respiratory distress
respiratory distress
acute respiratory syndrome (sars)
Holy Medical Center
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations